Breast-cancer adjuvant therapy with zoledronic acid

New England Journal of Medicine

Volumn 366, Issue 2, 2012, Pages 188-189

  Van Der Vliet, Hans J ^a   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPENTENYL DIPHOSPHATE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; GAMMA DELTA T LYMPHOCYTE; HUMAN; LETTER; PRIORITY JOURNAL; BREAST TUMOR; FEMALE; NOTE;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 84855985179     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1113049     Document Type: Letter

References (5)

1. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365: 1396-405.
2. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91. [Erratum, N Engl J Med 2009;360: 2379.]
3. Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8.
4. Lang JM, Kaikobad MR, Wallace M, et al. Pilot trial of interleukin- 2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell cancer. Cancer Immunol Immunother 2011;60:1447-60.
5. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8. (Pubitemid 36152311)